The global renal biomarker market is on a robust growth trajectory, projected to surge from USD 1,541.2 million in 2024 to an impressive USD 3,031.8 million by 2034. This growth represents a compound annual growth rate (CAGR) of 7%, highlighting the rising demand for advanced diagnostic solutions in kidney health.
A significant driver of this market expansion is the escalating prevalence of chronic kidney diseases (CKD) worldwide. Biomarker-based diagnostic tools are critical for the early detection and intervention of CKD, leading to improved patient outcomes and better management strategies. The increasing awareness of kidney health, along with the rising incidence of diabetes and hypertension, further fuels market growth.
Innovative advancements in biomarker discovery technologies are also contributing to this trend. Techniques such as omics approaches and high-throughput screening are accelerating the identification of novel biomarkers, enhancing diagnostic accuracy and clinical utility. These technological strides are vital for meeting diverse diagnostic needs and improving the reliability of biomarker assays.
Despite this promising outlook, the market faces challenges related to the variability in biomarker expression across different patient populations and disease stages. This variability can hinder the standardization and reproducibility of biomarker assays, limiting their clinical utility. Addressing these challenges is essential for the sustained growth and adoption of biomarker-based diagnostics in clinical settings.
As the global healthcare landscape continues to evolve, the renal biomarker market is poised to play a critical role in the early diagnosis and management of CKD. Stakeholders in the healthcare industry are encouraged to invest in research and development to overcome existing challenges and leverage emerging opportunities in this dynamic market.
Key Takeaways from the Market Study:
- By biomarker type, the functional biomarker is accounted to hold a market share of 54.9% in 2024.
- The United States is expected to register at a CAGR of 7.8% by 2034.
- The United Kingdom registers significant growth, projected at a CAGR of 8.5% by 2034.
- Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7% in 2024.
“The rising demand for biomarker-based diagnostic solutions to address the escalating CKD epidemic propels market growth, as healthcare providers prioritize preventive measures and proactive management of kidney health,” comments a Future Market Insights analyst.
Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report!
Competitive Landscape:
Multinational corporations, biotechnology firms, and academic institutions characterize the competitive landscape of the renal biomarker market.
Lucrative key players dominate the market with their innovative biomarker assays and extensive research expertise, driving market competition and innovation.
Some of the key developments are:
- In November 2022, Revelation Biosciences Inc. announced the results of a recent exploratory biomarker analysis, unveiling clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) and acute kidney injury (AKI).
- In 2023, Siemens Healthineers AG made a significant advancement in the renal biomarker market by introducing a novel biomarker panel to improve the diagnosis and management of renal diseases.
Key Companies Profiled:
- Abbott Laboratories
- BioPorto Diagnostics AS
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Nexelis (Pacific Biomarkers)
- BioMérieux
- Sphingotec GmbH
- Randox Laboratories Ltd
- Siemens Healthineers AG
- Beckman Coulter Inc. (Danaher Corporation)
- Bio-Rad Laboratories Inc.
Key Segments:
By Biomarker:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-regulated Proteins
- Neutrophil Gelatinase-Associated Lipocalin
- Kidney Injury Molecule-1
- Interleukin-18
- Others
By Diagnostic Technique:
- Enzyme Linked Immunosorbent Assay (ELISA)
- Particle-Enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography-Mass Spectrometry (LS-MS)
By End User:
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
- Hospitals
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube